Obamacare’s Repeal: What to Expect

Posted by Ed Schoonveld on Mon, Jan 16, 2017

 
It has been difficult to predict what repealing and replacing the Affordable Care Act (ACA), the signature legislation from President Barack Obama, will mean for the public and for the insurance and pharmaceutical industries. The lack of Republican consensus behind a single alternative plan and the uncertainty of President-elect Donald Trump’s actions have turned any projection into mere speculation. However, recent Republican steps and political reality are now starting to help clarify what the likely outcome of “repeal and replace” may be.


>
Read More

Brexit’s Impact on the EU’s Drug-Pricing Climate

Posted by Ed Schoonveld on Thu, Jun 30, 2016


Surprised and stunned by the U.K’s vote last Friday to exit the European Union, the world is experiencing a collective panic. However, currency and stock devaluations have mainly been driven by uncertainty rather than solid projections of corporate performance gaps, all of which has been further enhanced and inflamed by the media in their constant quest for better ratings.


>
Read More